Oxidative stress and modification of blood proteins in children with inflammatory bowel diseases

Introduction. Inflammatory bowel diseases (IBD) including Crohn’s disease (CD) and ulcerative colitis (UC) are chronic inflammatory diseases with an autoimmune attack on the gastrointestinal tract. Insufficient knowledge of the pathogenesis and the lack of reliable biomarkers of the severity of the condition in IBD dictates the need to search for new prognostic markers to assess the condition and effectiveness of therapy in IBD patients during remission and exacerbation of diseases.

The aim of the work was to evaluate the protein profile, the amount of ischemia-modified albumin (IMA) and the content of 3-nitrotyrosine (3-NT) in the blood serum in IBD children.

Materials and methods. In the blood serum of twenty two children in accordance with the pediatric indices of PCDAI/PUC disease activity in remission and exacerbation of IBD, electrophoretic separation of serum proteins was performed on the Hydrases 2 scan focusing device (Sebia). The content of IMA was determined by colorimetric method, 3-NT — by enzyme immunoassay (Hycult-Biotech, USA).

Results. The article presents data on the content of fractions of albumin (A) and globulins, IMA, and 3-NT in the blood serum in children with different severity of IBD (CD and UC), corresponding to remission and exacerbation of diseases. It was shown that the more severe the condition, the more pronounced the decrease in A with an increase in the fraction of acute phase proteins and a decrease in the albumin/globulin index (A/G). Simultaneously with a decrease in the level of A, the content of IMA and 3-NT indicators of oxidative and nitrosative stress increases.

Conclusion. The results obtained indicate modifications of serum proteins and the presence of oxidative and nitrosative stress in children with severe IBD. Due to the fact that such changes are typical for hypoxic brain damage and hyperstimulation of glutamate receptors (GluRc) of neurons, it is suggested that the indicators of oxidative and nitrosative stress in IBD children are associated with the possible development of disorders in the brain through GluRc activation.

Contribution:
Sorokina E.G., Reutov V.P. — the concept and writing of the text;
Radygina T.V., Petrichuk S.V., Afanasyeva S.A. — collection and processing of the material;
Bakaeva Z.V. — statistics;
Smirnov I.E., Potapov A.S. — editing.
All co-authors — approval of the final version of the article, responsibility for the integrity of all parts of the article.

Acknowledgment. The study had no sponsorship.

Conflict of interest. The authors declare no conflict of interest.

Received: June 08, 2023
Accepted: June 20, 2023
Published: August 31, 2023

1. Wagatsuma K., Yokoyama Y., Nakase H. Role of biomarkers in the diagnosis and treatment of inflammatory bowel disease. Life (Basel). 2021; 11(12): 1375. https://doi.org/10.3390/life11121375

2. Singh S., Ananthakrishnan A.N., Nguyen N.H., Cohen B.L., Velayos F.S., Weiss J.M., et al. AGA clinical practice guideline on the role of biomarkers for the management of ulcerative colitis. Gastroenterology. 2023; 164(3): 344–72. https://doi.org/10.1053/j.gastro.2022.12.007

3. Bar-Or D., Lau E., Winkler J.V. A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia-a preliminary report. J. Emerg. Med. 2000; 19(4): 311–5. https://doi.org/10.1016/s0736-4679(00)00255-9

4. Shevtsova A., Gordiienko I., Tkachenko V., Ushakova G. Ischemia-modified albumin: origins and clinical implications. Dis. Markers. 2021; 2021: 9945424. https://doi.org/10.1155/2021/9945424

5. Lee P., Wu X. Review: modifications of human serum albumin and their binding effect. Curr. Pharm. Des. 2015; 21(14): 1862–5. https://doi.org/10.2174/1381612821666150302115025

6. Watanabe H., Imafuku T., Otagiri M., Maruyama T. Clinical implications associated with the posttranslational modification-induced functional impairment of albumin in oxidative stress-related diseases. J. Pharm. Sci. 2017; 106(9): 2195–203. https://doi.org/10.1016/j.xphs.2017.03.002

7. Jena I., Nayak S.R., Behera S., Singh B., Ray S., Jena D., et al. Evaluation of ischemia modified albumin, oxidative stress, and antioxidant status in acute ischemic stroke patients. J. Nat. Sci. Biol. Med. 2017; 8(1): 110–3. https://doi.org/10.4103/0976-9668.198346

8. Encinas J.M., Serrano J., Bentura M.L., Castro-Blanco S., Fernández A.P., Rodrigo J. Nitric oxide system and protein nitration are modified by an acute hypobaric hypoxia in the adult rat hippocampus. J. Neuropathol. Exp. Neurol. 2003; 62(8): 863–77. https://doi.org/10.1093/jnen/62.8.863

9. Menon B., Ramalingam K., Krishna V. Study of ischemia modified albumin as a biomarker in acute ischaemic stroke. Ann. Neurosci. 2018; 25(4): 187–90. https://doi.org/10.1159/000488188

10. Okda M.A., Kabany R.A.E., Soliman H.S., Kholy M.S.E. Ischemia-modified albumin for evaluating severity and predicting prognosis in patients with acute cerebrovascular disease. Menoufia Med. J. 2020; 33(3): 1072–6. https://doi.org/10.4103/mmj.mmj_65_19

11. Wayenberg J.L., Ransy V., Vermeylen D., Damis E., Bottari S.P. Nitrated plasma albumin as a marker of nitrative stress and neonatal encephalopathy in perinatal asphyxia. Free Radical Biol. Med. 2009; 47(7): 975–82. https://doi.org/10.1016/j.freeradbiomed.2009.07.003

12. Gulpamuk B., Tekin K., Sonmez K., Inanc M., Neselioglu S., Erel O., et al. The significance of thiol/disulfide homeostasis and ischemia-modified albumin levels to assess the oxidative stress in patients with different stages of diabetes mellitus. Scand. J. Clin. Lab. Invest. 2018; 78(1-2): 136–42. https://doi.org/10.1080/00365513.2017.1422540

13. Bal W., Sokołowska M., Kurowska E., Faller P. Binding of transition metal ions to albumin: sites, affinities and rates. Biochim. Biophys. Acta. 2013; 1830(12): 5444–55. https://doi.org/10.1016/j.bbagen.2013.06.018

14. Christenson R.H., Duh S.H., Sanhai W.R., Wu A.H., Holtman V., Painter P., et al. Characteristics of an Albumin Cobalt Binding Test for assessment of acute coronary syndrome patients: a multicenter study. Clin. Chem. 2001; 47(3): 464–70.

15. Kundaktepe B.P., Sozer V., Durmus S., Kocael P.C., Kundaktepe F.O., Papila C., et al. The evaluation of oxidative stress parameters in breast and colon cancer. Medicine. 2021; 100(11): e25104. https://doi.org/10.1097/MD.0000000000025104

16. Berenshtein E., Mayer B., Goldberg C., Kitrossky N., Chevion M. Patterns of mobilization of copper and iron following myocardial ischemia: possible predictive criteria for tissue injury. J. Mol. Cell Cardiol. 1997; 29(11): 3025–34. https://doi.org/10.1006/jmcc.1997.0535

17. Rempel J., Grover K., El-Matary W. Micronutrient deficiencies and anemia in children with inflammatory bowel disease. Nutrients. 2021; 13(1): 236. https://doi.org/10.3390/nu13010236

18. Lee E., Eom J.E., Jeon K.H., Kim T.H., Kim E., Jhon G.J., et al. Evaluation of albumin structural modifications through cobalt-albumin binding (CAB) assay. J. Pharm. Biomed. Anal. 2014; 91: 17–23. https://doi.org/10.1016/j.jpba.2013.12.003

19. Darwish R.S., Amiridze N., Aarabi B. Nitrotyrosine as an oxidative stress marker: evidence for involvement in neurologic outcome in human traumatic brain injury. J. Trauma. 2007; 63(2): 439–42. https://doi.org/10.1097/TA.0b013e318069178a

20. Felipo V., Urios A., Valero P., Sánchez M., Serra M.A., Pareja I., et al. Serum nitrotyrosine and psychometric tests as indicators of impaired fitness to drive in cirrhotic patients with minimal hepatic encephalopathy. Liver. Int. 2013; 33(10): 1478–89. https://doi.org/10.1111/liv.12206

21. Sun Y.C., Chang P.Y., Tsao K.C., Wu T.L., Sun C.F., Wu L.L., et al. Establishment of a sandwich ELISA using commercial antibody for plasma or serum 3-nitrotyrosine (3NT). Elevation in inflammatory diseases and complementary between 3NT and myeloperoxidase. Clin. Chim. Acta. 2007; 378(1-2): 175–80. https://doi.org/10.1016/j.cca.2006.11.014

22. Wu L.L., Wu J.T. Serum 3-Nitrotyrosine may be elevated with the exposure to acute inflammatory risk factors such as unhealthy diet, pollutant, drug and psychosocial stress. J. Biomed. Lab. Sci. 2007; 19(4): 113–6.

23. Sorokina E.G., Semenova Zh.B., Reutov V.P., Arsenieva E.N., Karaseva O.V., Fisenko A.P., et al. Brain biomarkers in children after mild and severe traumatic brain injury. Acta Neurochir. Suppl. 2021; 131: 103–7. https://doi.org/10.1007/978-3-030-59436-7_22

24. Sorokina E.G., Semenova Zh.B., Bazarnaya N.A., Meshcheryakov S.V., Reutov V.P., Goryunova A.V., et al. Autoantibodies to glutamate receptors and products of nitric oxide metabolism in serum in children in the acute phase of craniocerebral trauma. Neurosci. Behav. Physiol. 2009; 39(4): 329–34. https://doi.org/10.1007/s11055-009-9147-1

25. Lombardi G., Dianzani C., Miglio G., Canonico P.L., Fantozzi R. Characterization of ionotropic glutamate receptors in human lymphocytes. Br. J. Pharmacol. 2001; 133(6): 936–44. https://doi.org/10.1038/sj.bjp.0704134

26. Zakirov R.Sh., Sorokina E.G., Karaseva O.V., Semenova Zh.A., Petrichuk S.V., Roshal’ L.M., et al. Functional state of mitochondria of peripheral blood lymphocytes in children with traumatic brain injury. Vestnik Rossiyskoy akademii meditsinskikh nauk. 2015; 70(6): 710–7. https://doi.org/10.15690/vramn568 https://elibrary.ru/vdldbz (in Russian)

27. Radygina T.V., Sorokina E.G., Petrichuk S.V., Kuptsova D.G., Kurbatova O.V., Potapov A.S., et al. Evaluation of the functional activity of CD39 ectonucleotidase in regulatory T cells in children with inflammatory bowel diseases. Meditsinskaya immunologiya. 2023; 25(2): 415–22. https://doi.org/10.15789/10.15789/1563-0625-EOT-2616 https://elibrary.ru/eyigyk (in Russian)

28. Reutov V.P., Sorokina E.G. Causal relationship between physiological and pathological processes in the brain and in the gastrointestinal tract: the brain-intestine axis. Biophys. (Oxf.). 2022; 67(6): 972–86. https://doi.org/10.1134/S0006350922060197

29. Facanali C.B.G., Sobrado Junior C.W., Fraguas Junior R., Facanali Junior M.R., Boarini L.R., Sobrado L.F., et al. The relationship of major depressive disorder with Crohn’s disease activity. Clinics (San Paulo). 2023; 78: 100188. https://doi.org/10.1016/j.clinsp.2023.100188

30. Clarke G., Kennedy P.J., Groeger J.A., Quigley E.M., Shanahan F., Cryan J.F., et al. Impaired cognitive function in Crohn’s disease: Relationship to disease activity. Brain Behav. Immun. Health. 2020; 5: 100093. https://doi.org/10.1016/j.bbih.2020.100093